scholarly journals The progesterone receptor is differentially expressed in epithelial ovarian cancer and its expression correlates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Progesterone Receptor ◽  
Epithelial Ovarian Cancer ◽  
Progression Free Survival ◽  
High Grade ◽  
Normal Ovary ◽  
Serous Ovarian Cancer ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Free Survival

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC), the most common type of EOC by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (2, 3). We found significant differential expression of the gene encoding the progesterone receptor, PGR, in high-grade serous ovarian tumors and in epithelial ovarian cancer broadly. PGR was expressed at lower levels in tumors from patients with high-grade serous ovarian cancer as compared to the normal ovary, and EOC patients whose tumors expressed low levels of PGR possessed significantly shorter progression-free survival than did those whose tumors expressed high levels of PGR. Multiple studies have described potential roles for the progesterone receptor in ovarian cancer, but our analysis is the first to demonstrate differential, decreased expression of PGR in tumors from patients with ovarian cancer and specifically in HGSC, in conjunction with unfavorable progression-free survival outcomes for ovarian cancer patients with low tumor expression of PGR.

scholarly journals Interleukin-16 expression associates with patient survival in high-grade serous ovarian cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
Global Gene Expression ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Significant Differential Expression ◽  
Free Survival

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with enhanced survival in high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of tumors from women diagnosed with HGSC with the best and worst progression-free survival (2). We found significant differential expression of the gene encoding the cytokine interleukin-16 (IL-16) when comparing tumor transcriptomes based on progression-free survival. IL-16 was expressed at significantly lower levels in high-grade serous ovarian tumors of women with the longest progression-free survival.

scholarly journals Expression of the interleukin-1 receptor antagonist associates with patient survival in high-grade serous ovarian cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Receptor Antagonist ◽  
Expression Profiles ◽  
Interleukin 1 ◽  
Gynecologic Cancer ◽  
Progression Free Survival ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Significant Differential Expression ◽  
Free Survival

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with enhanced survival in high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of tumors from women diagnosed with HGSC with the best and worst progression-free survival (2). We found significant differential expression of the gene encoding the receptor antagonist for the cytokine interleukin-1 (IL-1) (IL-1RN) when comparing tumor transcriptomes based on progression-free survival. IL-1RN was expressed at significantly lower levels in high-grade serous ovarian tumors of women with the longest progression-free survival.

scholarly journals NLRP7 expression associates with patient survival in high-grade serous ovarian cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
Global Gene Expression ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Significant Differential Expression ◽  
Free Survival

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with enhanced survival in high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of tumors from women diagnosed with HGSC with the best and worst progression-free survival (2). We found significant differential expression of the gene encoding the NLR family pyrin domain containing 7 (NLRP 7) when comparing tumor transcriptomes based on progression-free survival. NLRP7 was expressed at significantly higher levels in high-grade serous ovarian tumors of women with the longest progression-free survival.

scholarly journals Differential expression of SLIT and NTRK-like family member 3 in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Family Member ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published and public microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding SLIT and NTRK-like family member 3, SLITRK3, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. SLITRK3 expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. SLITRK3 expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of SLITRK3 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. SLITRK3 may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of sarcospan in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding sarcospan, SSPN, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. SSPN expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. SSPN expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of SSPN is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. SSPN may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of phosphodiesterase 5A in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding phosphodiesterase 5A, PDE5A, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. PDE5A expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. PDE5A expression correlated with progression-free survival in patients with p53 mutant ovarian cancer. These data indicate that expression of PDE5A is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. PDE5A may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of trophinin associated protein in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding trophinin associated protein, TROAP, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. TROAP expression was significantly higher in high-grade serous ovarian tumors relative to normal fallopian tube. TROAP expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of TROAP is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. TROAP may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of hematopoietic SH2 domain containing in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Progression Free Survival ◽  
Sh2 Domain ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding hematopoietic SH2 domain containing, HSH2D, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. HSH2D expression was significantly higher in high-grade serous ovarian tumors relative to normal fallopian tube. HSH2D expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of HSH2D is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. HSH2D may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

Sign in / Sign up

Export Citation Format

Share Document